Intrahepatic cholangiocarcinoma (iCCA) is recognized worldwide as the second leading cause of morbidity and mortality among primary liver cancers, showing a continuously increasing incidence rate in recent years. iCCA aggressiveness is revealed through its rapid and silent intrahepatic expansion and spread through the lymphatic system leading to late diagnosis and poor prognoses. Multi-omics studies have aggregated information derived from single-omics data, providing a more comprehensive understanding of the phenomena being studied. These approaches are gradually becoming powerful tools for investigating the intricate pathobiology of iCCA, facilitating the correlation between molecular signature and phenotypic manifestation. Consequently, preliminary stratifications of iCCA patients have been proposed according to their “omics” features opening the possibility of identifying potential biomarkers for early diagnosis and developing new therapies based on personalized medicine (PM). The focus of this review is to provide new and advanced insight into the molecular pathobiology of the iCCA, starting from single- to the latest multi-omics approaches, paving the way for translating new basic research into therapeutic practices.
肝内胆管癌（iCCA）被全球公认为原发性肝癌中发病率和死亡率的第二大原因，近年来其发病率持续上升。iCCA的侵袭性表现为其快速且隐匿的肝内扩张及通过淋巴系统扩散，导致诊断延迟和预后不良。多组学研究整合了来自单一组学数据的信息，为所研究现象提供了更全面的理解。这些方法正逐渐成为探究iCCA复杂病理生物学的有力工具，有助于建立分子特征与表型表现之间的关联。因此，根据iCCA患者的“组学”特征已提出初步分层方案，这为识别早期诊断的潜在生物标志物以及开发基于个性化医疗（PM）的新疗法提供了可能。本综述旨在从单一组学到最新的多组学方法，为iCCA的分子病理生物学提供新颖而深入的见解，从而为将新的基础研究成果转化为治疗实践铺平道路。
肿瘤(癌症)患者之家